Delcath Systems (NASDAQ:DCTH) Announces Quarterly Earnings Results

Delcath Systems (NASDAQ:DCTH) announced its quarterly earnings results on Tuesday. The company reported ($0.48) EPS for the quarter, beating the consensus estimate of ($0.67) by $0.19, RTT News reports. The company had revenue of $0.54 million for the quarter, compared to analyst estimates of $0.48 million. Delcath Systems had a negative net margin of 2,308.86% and a negative return on equity of 1,007.65%. During the same quarter last year, the business earned ($0.86) earnings per share.

Delcath Systems Price Performance

Shares of NASDAQ:DCTH traded down $0.23 during midday trading on Thursday, reaching $4.86. The company had a trading volume of 175,898 shares, compared to its average volume of 217,690. Delcath Systems has a 1-year low of $2.25 and a 1-year high of $7.99. The company has a fifty day simple moving average of $4.34 and a two-hundred day simple moving average of $3.84. The company has a current ratio of 3.30, a quick ratio of 3.11 and a debt-to-equity ratio of 0.08.

Insider Buying and Selling at Delcath Systems

In other news, Director Gil Aharon acquired 26,882 shares of the business’s stock in a transaction that occurred on Tuesday, March 19th. The stock was acquired at an average cost of $3.72 per share, for a total transaction of $100,001.04. Following the completion of the acquisition, the director now owns 1,069,710 shares in the company, valued at $3,979,321.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 21.10% of the company’s stock.

Institutional Investors Weigh In On Delcath Systems

Several hedge funds and other institutional investors have recently made changes to their positions in DCTH. Vanguard Group Inc. raised its holdings in Delcath Systems by 19.7% in the 4th quarter. Vanguard Group Inc. now owns 522,008 shares of the company’s stock valued at $2,172,000 after acquiring an additional 85,948 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Delcath Systems by 85.8% during the second quarter. Geode Capital Management LLC now owns 116,536 shares of the company’s stock valued at $679,000 after purchasing an additional 53,803 shares during the period. Cibc World Market Inc. raised its stake in shares of Delcath Systems by 4.0% in the first quarter. Cibc World Market Inc. now owns 88,751 shares of the company’s stock valued at $568,000 after purchasing an additional 3,432 shares in the last quarter. Northern Trust Corp lifted its position in Delcath Systems by 82.7% in the fourth quarter. Northern Trust Corp now owns 60,667 shares of the company’s stock worth $252,000 after purchasing an additional 27,458 shares during the period. Finally, BlackRock Inc. lifted its position in Delcath Systems by 183.7% in the second quarter. BlackRock Inc. now owns 47,180 shares of the company’s stock worth $275,000 after purchasing an additional 30,548 shares during the period. 61.12% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on DCTH shares. HC Wainwright boosted their price target on Delcath Systems from $18.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday. StockNews.com raised shares of Delcath Systems to a “sell” rating in a report on Wednesday. One research analyst has rated the stock with a sell rating and four have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $18.50.

About Delcath Systems

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.